PD-1/PD-L1 inhibitor

Phase 2Small molecule

SSecond Affiliated Hospital of Soochow University

PD-1/PD-L1 inhibitor is one of 114 small molecule programs targeting Lung Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

113

Competitors

Pipeline

Status by Indication[3][1]

Indication

Lung CancerActive, not recruiting

Biliary Tract CancerActive, not recruiting

Non-Small Cell Lung CancerActive, not recruiting

Hepatocellular CarcinomaActive, not recruiting

Lung CancerPhase 1

Active, not recruiting

Biliary Tract CancerPreclinical

Active, not recruiting

Non-Small Cell Lung CancerPhase 2

Active, not recruiting

Hepatocellular CarcinomaPhase 2

Active, not recruiting

Competition

Competitive Landscape

1639 competitors in Non-Small Cell Lung Cancer

#DrugCompanyPhaseTrials

Yervoy

Bristol-Myers Squibb

Preclinical

31 2

Gemzar

GGynecologic Oncology Group

Preclinical

72 3

PD-1/PD-L1 inhibitor

SSecond Affiliated Hospital of Soochow University

Phase 2

3 4

PORTRAZZA

Eli Lilly

Preclinical

8 5

Vizimpro

Pfizer

Preclinical

4 6

Gilotrif

Boehringer Ingelheim

Preclinical

12 7

Ofev

Boehringer Ingelheim

Preclinical

7 8

Immunotherapy

Bristol-Myers Squibb

Preclinical

12 9

Aqupla

Jiangsu Simcere Pharmaceutical Co., Ltd.

Preclinical

—10

Ftorafur

TThe First Affiliated Hospital with Nanjing Medical University

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 2Recruiting

IDH1 Mutation

NCT07282262

Q4 2027

Phase 2Not yet recruiting

Hepatocellular Carcinoma

NCT07230314

Q1 2029

Not yet recruiting

Biliary Tract Cancer

NCT07466238

Clinical

Trials by Indication[1]

Non-Small Cell Lung Cancer3 trials

Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)

Unknown status·SSecond Affiliated Hospital of Soochow University·Phase 2·NCT05603013·45 enrolled

A Clinical Study of Recombinant Human Vascular Endothelial Inhibitor in Combination With PRaG for Advanced Refractory Non-small Cell Lung Cancer

Unknown status·SSecond Affiliated Hospital of Soochow University·Phase 2·NCT06047860·30 enrolled

Radiotherapy Combined With Immunotherapy for Brain Metastases of Non-small Cell Lung Cancer

Suspended·TTongji Hospital··NCT04835025·200 enrolled

Hepatocellular Carcinoma1 trial

Sequential Transarterial Chemoembolization (TACE), Stereotactic Body Radiation Therapy (SBRT), and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma Treated With Donafenib

Not yet recruiting·JJinling Hospital, China·Phase 2·NCT07230314·34 enrolled

IDH1 Mutation1 trial

An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.

Recruiting·PPeking Union Medical College Hospital·Phase 2·NCT07282262·300 enrolled

Lung Cancer1 trial

The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT05735028·8 enrolled

Biliary Tract Cancer1 trial

HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer

Not yet recruiting·PPeking University··NCT07466238·40 enrolled

2 more indications

Pneumonitis1 trial

Interstitial Pneumonitis Associated With EGFR-TKI and Combined With PD-1/PD-L1

Completed·UUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology··NCT07036016·67,818 enrolled

Advanced Refractory Solid Tumors1 trial

Thymalfasin-based PRaG Mode for Advanced Refractory Solid Tumors

Unknown status·SSecond Affiliated Hospital of Soochow University·Phase 2·NCT05790447·60 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for PD-1/PD-L1 inhibitor. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — PD-1/PD-L1 inhibitor compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for PD-1/PD-L1 inhibitor. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Second Affiliated Hospital of Soochow University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSecond Affiliated Hospital of Soochow University

PD-1/PD-L1 inhibitor

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Q4 2027

Q1 2029

Trials by Indication[1]

Non-Small Cell Lung Cancer3 trials

Hepatocellular Carcinoma1 trial

IDH1 Mutation1 trial

Lung Cancer1 trial

Biliary Tract Cancer1 trial

Pneumonitis1 trial

Advanced Refractory Solid Tumors1 trial

References

Drug Info

Quick Facts

Related News